CHAPTER 51 Gamma Knife® Radiosurgery for Convexity and Parasagittal Meningiomas
INTRODUCTION
Meningiomas arise from arachnoidal cap cells, and more than 90% of them are benign.1,2 As these tumors are encapsulated, complete resection is the preferred treatment. However; complete tumor resection is not always possible. Even if complete resection is successfully achieved, tumor recurrence is not uncommon during the long-term follow-up period. It has been reported that 20% to 30% of patients who had complete resection of their tumor, experienced recurrence in the follow-up period of 10 to 15 years.3–5 In cases of residual tumor, long-term tumor progression rates are higher, and tumor growth is demonstrated in 60% to 90% at follow-up of longer than 10 years.3–6 Therefore, in incompletely resected meningiomas, especially in atypical or anaplastic meningiomas, external-beam radiation therapy (EBRT) has been commonly performed, resulting in improved local tumor control.7–9 However, despite improved local tumor control, EBRT can cause long-term complications such as cognitive decline, pituitary insufficiency, or radiation-induced tumors. Recently, stereotactic radiosurgery has emerged as an alternative to EBRT or surgical resection and has gained more and more importance in the management of meningiomas, especially in those that cannot be completely resected, such as many skull-base meningiomas.
RADIOSURGICAL TECHNIQUES
At our institute, Gamma Knife radiosurgery is performed using the Leksell stereotactic frame (Model G; Elekta Instruments, Sweden, AB). During Gamma Knife radiosurgery; first, the frame is applied to the patient under mild sedation and local anesthesia, then MRI or computed tomography (CT) scan is performed. Axial and coronal T1-weighted images with contrast enhancement are usually used for dose-planning. Patient treatment is planned using GammaPlan® software. After dose planning, GKRS is performed. Axial gadolinium-enhanced T1-weighted MR images obtained in a 47-year-old woman, showing a left convexity meningioma, which has been treated in our institution with GKRS at a margin dose of 14 Gy (A), is presented in Figure 51-1. It is important to target the entire tumor, including the dural tail to achieve long-term tumor control, in the dose planning for meningiomas.
TUMOR CONTROL AND PREDICTIVE FACTORS
To date, numerous investigators have reported the results of stereotactic radiosurgery application to meningiomas in various locations, demonstrating 75% to 100% local tumor control rates at 5 to 10 years.2,10–25 To the best of our knowledge, there are only few large studies focusing on superficially located meningiomas treated alone with stereotactic radiosurgery, as most neurosurgeons prefer surgical resection to radiosurgery to treat this type of benign tumor. According to a multicenter review in 1998 by Kondziolka and colleagues,16 in 203 patients with parasagittal meningiomas, all patients were treated by GKRS and the actuarial 5-year tumor control rates were 93% ± 4% and 60% ± 10% in the primary and adjuvant treatment group, respectively. None of the patients having tumors smaller than 7.5 cm3, and no prior open surgery, required additional therapy and their neurologic function have remained stable. The authors also insisted that most treatment failures resulted from remote tumor growth. The rate of transient, symptomatic edema after GKRS was 16% and this complication was more common with larger tumors within 2 years. Kondziolka and colleagues32 reported 972 patients with intracranial meningiomas, and 239 meningiomas were located at the parasagittal region and convexity. The morbidity rate for the parasagittal location was 9.7%. Kollova and colleagues2 reported the treatment results of 368 patients who had benign meningiomas in various locations with a median follow-up of 60 months. They demonstrated an actuarial 5-year tumor control rate of 98% and a postradiosurgical peritumoral edema rate of 15%. They found that treatment failures significantly occurred in men and in tumors treated at a marginal dose of less than 12 Gy. Significant risk factors for postradiosurgical edema were patient age older than 60 years, no prior surgery, prelesional edema before radiosurgery, tumor volume greater than 10 cm3, tumor location in the anterior fossa, and a marginal dose of greater than 16 Gy. Kim and colleagues15 found postradiosurgical symptomatic edema in 43% of superficially located meningiomas. They documented that parasagittal lesions had a tendency to severe postradiosurgical edema. Chang and colleagues1 found in their meningioma series of 179 patients that convexity, parasagittal and falx meningiomas that were deeply embedded in the cortex developed postradiosurgical edema more frequently and tumor location was the only risk factor for it. Approximately 60% of patients who had postradiosurgical edema were asymptomatic and their symptoms were all transient. Postradiosurgical edema was found in four of 79 skull-base meningiomas (5%), compared with 26 of 52 hemispheric meningiomas (50%). Kalapurakal and colleagues26 suggested that parasagittal location, presence of pretreatment edema, and sagittal sinus occlusion were significant predictors for the development of brain edema after stereotactic radiosurgery and radiation therapy. They noted that all of the patients who developed severe posttreatment life-threatening panhemispheric edema had parasagittal meningiomas.
Concerning atypical and anaplastic meningiomas, it is difficult to achieve long-term tumor control even with relatively high-dose radiosurgery. Harris and colleagues27